These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 14518704

  • 1. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M.
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [Abstract] [Full Text] [Related]

  • 2. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F.
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [Abstract] [Full Text] [Related]

  • 3. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.
    Antivir Ther; 2005 Jul; 10(1):73-81. PubMed ID: 15751765
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients.
    Seminari E, Tinelli C, Minoli L, Sacchi P, Filice G, Zocchetti C, Meneghetti G, Bruno R, Maserati R.
    Antivir Ther; 2002 Sep; 7(3):175-80. PubMed ID: 12487384
    [Abstract] [Full Text] [Related]

  • 5. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M, Schwarzinger M, Amellal B, Gourlain K, Bui P, Prévot M, Deleuze J, Morini JP, Gorin I, Calvez V, Dupin N.
    J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.
    AIDS; 2006 Oct 03; 20(15):1941-50. PubMed ID: 16988515
    [Abstract] [Full Text] [Related]

  • 7. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive.
    Bergersen BM, Sandvik L, Ellingsen I, Bruun JN.
    HIV Med; 2005 Jul 03; 6(4):260-7. PubMed ID: 16011531
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, DAD study group.
    AIDS; 2003 May 23; 17(8):1179-93. PubMed ID: 12819520
    [Abstract] [Full Text] [Related]

  • 10. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy.
    Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggini V, Lepri AC, Mologni D, Mazzotta F, Monforte AD, Mussini C, Cossarizza A, Galli M, Icona Foundation Study Group.
    AIDS; 2008 Sep 12; 22(14):1769-78. PubMed ID: 18753860
    [Abstract] [Full Text] [Related]

  • 11. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.
    Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, Diakité N, Daudié A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N'Dri-Yoman T, Salamon R, ANRS 1203 Study Group.
    Antivir Ther; 2003 Oct 12; 8(5):385-93. PubMed ID: 14640385
    [Abstract] [Full Text] [Related]

  • 12. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.
    HIV Med; 2005 Nov 12; 6(6):396-402. PubMed ID: 16268821
    [Abstract] [Full Text] [Related]

  • 13. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
    Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM, CHORUS Program Team.
    J Clin Epidemiol; 2004 Jan 12; 57(1):89-97. PubMed ID: 15019015
    [Abstract] [Full Text] [Related]

  • 14. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Jan 12; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.
    Antivir Ther; 2003 Oct 12; 8(5):379-84. PubMed ID: 14640384
    [Abstract] [Full Text] [Related]

  • 17. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, Swiss HIV Cohort Study.
    Clin Infect Dis; 2008 Oct 15; 47(8):1093-101. PubMed ID: 18783328
    [Abstract] [Full Text] [Related]

  • 18. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.
    Clin Infect Dis; 2005 Nov 01; 41(9):1326-32. PubMed ID: 16206110
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N, Bagheri H, Sommet A, Delpierre C, Marion-Latard F, Massip P, Aquilina C, Bonnet E, Obadia M, Labau E, Montastruc JL, Bernard J.
    Pharmacotherapy; 2006 Feb 01; 26(2):154-61. PubMed ID: 16466321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.